APA (7th ed.) Citation

J, P., B, H., J, C., FA, G. F., A, G., AG, K., . . . A, R. (2025). Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies. Annals of hematology, 104(6), 3199. https://doi.org/10.1007/s00277-025-06449-0

Chicago Style (17th ed.) Citation

J, Panse, et al. "Patient-reported Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Crovalimab and Approved C5 Inhibitors in the Phase III COMMODORE 2 and 1 Studies." Annals of Hematology 104, no. 6 (2025): 3199. https://doi.org/10.1007/s00277-025-06449-0.

MLA (9th ed.) Citation

J, Panse, et al. "Patient-reported Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Crovalimab and Approved C5 Inhibitors in the Phase III COMMODORE 2 and 1 Studies." Annals of Hematology, vol. 104, no. 6, 2025, p. 3199, https://doi.org/10.1007/s00277-025-06449-0.